Luteolin

Effects of luteolin and quercetin, inhibitors of tyrosine kinase, on cell growth and metastasis-associated properties in A431 cells overexpressing epidermal growth factor receptor: Y.T. Huang, et al.; Br. J. Pharmacol. 128, 999 (1999) | Inhibition of alpha-glucosidase and amylase by luteolin, a flavonoid: J.S. Kim, et al.; Biosci. Biotechnol. Biochem. 64, 2458 (2000) | Luteolin, an emerging anti-cancer flavonoid, poisons eukaryotic DNA topoisomerase I: A.R. Chowdhury, et al.; Biochem. J. 366, 653 (2002) | Inhibition of matrix-proteases by polyphenols: Chemical insights for anti-inflammatory and anti-invasion drug design: L. Sartor, et al.; Biochem. Pharmacol. 64, 229 (2002) | Luteolin inhibits the nuclear factor-kappa B transcriptional activity in Rat-1 fibroblasts: S.H. Kim, et al.; Biochem. Pharmacol. 66, 955 (2003) | Inhibition of 15-lipoxygenases by flavonoids: Structure-activity relations and mode of action: C.D. Sadik, et al.; Biochem. Pharmacol. 65, 773 (2003) | Induction of apoptosis by luteolin through cleavage of Bcl-2 family in human leukemia HL-60 cells: A.C. Cheng, et al.; Eur. J. Pharmacol. 509, 1 (2005) | Luteolin inhibits insulin-like growth factor 1 receptor signaling in prostate cancer cells: J. Fang, et al.; Carcinogenesis 28, 713 (2007) | Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1: S. Jang, et al.; PNAS 105, 7534 (2008) | Inhibition of fatty acid synthase by luteolin post-transcriptionally down-regulates c-Met expression independent of proteosomal/lysosomal degradation: D.T. Coleman, et al.; Mol. Cancer Ther. 8, 214 (2009) | Physicochemical properties and antioxidant activities of luteolin-phospholipid complex: K. Xu, et al.; Molecules 14, 3486 (2009) | Luteolin inhibits adipogenic differentiation by regulating PPARgamma activation: H.S. Park, et al.; Biofactors 35, 373 (2009) | Functional activation of monoamine transporters by luteolin and apigenin isolated from the fruit of Perilla frutescens: G. Zhao, et al.; Neurochem. Int. 56, 168 (2010) | Apigenin, Chrysin, and Luteolin Selectively Inhibit Chymotrypsin-Like and Trypsin-Like Proteasome Catalytic Activities in Tumor Cells: Y.-X. Wu & X. Fang; Planta Med. 76, 128 (2010) | Luteolin, a non-selective competitive inhibitor of phosphodiesterases 1-5, displaced [3H]-rolipram from high-affinity rolipram binding sites and reversed xylazine/ketamine-induced anesthesia: M.C. Yu, et al.; Pulmon. Gastrointest. Urogen. Pharmacol. 627, 269 (2010) | Luteolin inhibits protein kinase C(epsilon) and c-Src activities and UVB-induced skin cancer: S. Byun, et al.; Cancer Res. 70, 2415 (2010) | Inhibition of cell survival, invasion, tumor growth and histone deacetylase activity by the dietary flavonoid luteolin in human epithelioid cancer cells: S. Attoub, et al.; Eur. J. Pharmacol. 651, 18 (2011) | Autophagy inhibitor chloroquine enhanced the cell death inducing effect of the flavonoid luteolin in metastatic squamous cell carcinoma cells: L. Verschooten, et al.; PLoS One 7, e48264 | Raf and PI3K are the molecular targets for the anti-metastatic effect of Luteolin: H.Y. Kim, et al.; Phytother. Res. 27, 1481 (2013) | Luteolin is a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses Notch4 signaling by blocking the activation of Y-box binding protein-1 (YB-1): K.M. Reipas, et al.; Oncotarget 4, 329 (2013)